Compare Supplements

Side-by-side comparison of 2 supplements

Cag5.0

Cagrilintide

Limited safety

Sgl8.5

Semaglutide

Limited safety

Evidence

Evidence Score5/10

Studies: 10

Meta-analyses: 2

Evidence Score8.5/10

Studies: 11

Meta-analyses: 2

Dosage & timing

Dosage:

Investigational — NO approved monotherapy dose. Phase-2 trials used once-weekly subcutaneous injection with stepwise escalation up to 4.5 mg maintenance. There is no approved standalone regimen; do not self-dose an unapproved drug.

Best Time:

Any time

Can take on empty stomach

Form:

Once-weekly subcutaneous injection (investigational only)

Dosage:

Prescription-only, clinician-titrated. Subcutaneous (Wegovy weight management: escalate to 2.4 mg once weekly; Ozempic diabetes: 0.5-2.0 mg once weekly). Oral (Rybelsus diabetes: 3-14 mg once daily). DO NOT self-dose.

Best Time:

Any time

Can take on empty stomach

Form:

Subcutaneous once-weekly injection (Ozempic / Wegovy)

What you'll notice

⚖️ Weight loss as monotherapy (phase-2 only)positive

Over 26 weeks

🔗 Larger weight loss with semaglutide (CagriSema)positive

Over 20-32 weeks

🩸 Improved glycemic controlpositive

By 32 weeks

🩸 Improved glycemic controlpositive

Weeks to months

⚖️ Substantial weight losspositive

Months (titrated over 16-20 weeks)

❤️ Reduced cardiovascular eventspositive

Months to years

Safety

Limited safety

Contraindications:

Not a dietary supplement and not an approved standalone drug — investigational; do not self-source grey-market vials
History of pancreatitis (amylin/incretin-class caution)
Pregnancy and breastfeeding

Drug Interactions:

Oral medications (delayed gastric emptying)
Insulin / insulin secretagogues (sulfonylureas)
GLP-1 / incretin drugs (e.g. semaglutide)

Side Effects:

NauseaConstipation / diarrhoeaInjection-site reactions

Limited safety

Contraindications:

Personal or family history of medullary thyroid carcinoma (MTC)
Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
Prior serious hypersensitivity to semaglutide or any GLP-1 receptor agonist

Drug Interactions:

Insulin and sulfonylureas
Oral medications (general)
Other GLP-1 receptor agonists

Side Effects:

NauseaVomiting / diarrhea / constipationGallbladder disease (cholelithiasis / cholecystitis)

How they work together

Like what you see? Add these to your stack.

See how they work together through biological pathways.

Build Your Stack

Want to compare more supplements?

Loading comparison...